Investment Stage

Focus Areas

About Investor

Samuel Bjork is a Partner at Digitalis Ventures who focuses on investments in E-commerce and Therapeutics at Seed stage, with investment ranges typically between $100K and $5.0M. His verified work background includes serving as a director on the boards of Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, T-Therapeutics, and Terray Therapeutics, demonstrating his deep involvement in guiding portfolio companies. Prior to Digitalis, Bjork was a member of the healthcare and clean energy practices at the Boston Consulting Group, bringing valuable consulting experience to his venture capital role. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University, providing strong academic credentials in both business and scientific disciplines.